CRISPR Therapeutics AG

CRISPR Therapeutics AG's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, CRISPR Therapeutics AG has 96.66M shares outstanding.

As of June 30, 2026, CRISPR Therapeutics AG maintains a current ratio of 17.85, meaning it holds 17.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG posted a negative return on equity (ROE) of -26.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.28, reflecting losses generated across the asset base. The company generates approximately 24,499.49 in revenue per employee across its workforce of 393.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG recorded 2.65M in income tax expense. The company reported a pretax loss of -392.23M and -394.88M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG generated 9.63M in revenue and converted that into -394.88M in net income, yielding earnings per share of -4.17. EBITDA reached -451.35M, while operating income came in at -467.71M.

As of June 30, 2026, CRISPR Therapeutics AG holds 2.07B in cash and equivalents against 686.01M in total debt, resulting in a net debt position of 258.09M. Total book value stands at 1.53B, with working capital of 1.96B providing operational flexibility.

CRISPR Therapeutics AG produced -323.50M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.53M in capital expenditures, free cash flow totaled -325.02M - equivalent to -3.43 per share.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG posted a gross margin of -1,691.26, reflecting its pricing power and cost economics. The operating margin of -4,857.64 and net profit margin of -4,101.26 provide insight into operational efficiency.